Biotech

Biotech Damian Garde

STAT Plus: Syndax’s leukemia drug succeeds in pivotal study

Biotech Jonathan Wosen

STAT Plus: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the fourth quarter: 16 stock-moving events to watch

Matt's Take Matthew Herper

STAT Plus: What we owe ALS patients — and why one company fell short

In the Lab Jason Mast

STAT Plus: Can the world still invent an HIV vaccine? Progress in one area creates new problem

Biotech Jason Mast

STAT Plus: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling

Biotech Allison DeAngelis

STAT Plus: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments

Biotech Damian Garde

STAT Plus: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm

Biotech Matthew Herper

STAT Plus: U.S. government’s next-gen Covid effort gives small biotech up to $433 million

Biotech Jason Mast

STAT Plus: Gene therapy death was caused by an unknown risk of the virus used, study suggests

Exclusive Mario Aguilar and Matthew Herper

STAT Plus: Biogen shutters digital health group, nixes Apple study, as part of cost cuts

Politics Sarah Owermohle

STAT Plus: With Menendez indictment, pharmaceutical industry could lose a key ally

Biotech Robert Weisman — Boston Globe and Jon Chesto — Boston Globe

STAT Plus: Cambridge announced as ‘investor catalyst’ hub for ARPA-H

Biotech Damian Garde

STAT Plus: Intercept, once a biotech trailblazer, sells itself for less than $1 billion

Biotech Andrew Joseph

STAT Plus: Early data are promising for autoimmune disease drug from Roivant Sciences’ Immunovant

Biotech Jonathan Wosen

STAT Plus: Ionis inches toward first solo drug launch with late-stage trial success for rare genetic disease therapy

First Opinion Leah Christl

STAT Plus: The problem with potential changes to the biosimilar regulatory framework

Biotech Damian Garde

STAT Plus: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds

Biotech Allison DeAngelis and Damian Garde

STAT Plus: What ever happened to biotech’s big comeback?

Biotech Andrew Joseph

STAT Plus: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial

Health Tech Lizzy Lawrence

STAT Plus: FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.

Biotech Jason Mast

STAT Plus: Travere kidney drug narrowly fails confirmatory trial following FDA approval

Biotech Damian Garde

STAT Plus: What to know about the polarizing ALS drug headed for FDA scrutiny

Adam's Take Adam Feuerstein

STAT Plus: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind

Biotech Jonathan Wosen

STAT Plus: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’

Exclusive Jason Mast

STAT Plus: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells

Biotech Allison DeAngelis

STAT Plus: Machine learning biotech raises $273 million in rare successful late-stage round

Biotech Damian Garde

STAT Plus: FDA panel endorses Alnylam’s heart drug — after picking apart its supporting data